Phase 2A, Double-blind, Randomized, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Saroglitazar Mg 4 mg Tablet Vs Placebo for Treating NAFLD in Women With Polycystic Ovary Syndrome (PCOS)
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2020
Price : $35 *
At a glance
- Drugs Saroglitazar (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Acronyms EVIDENCES VII
- Sponsors Zydus Discovery DMCC
- 06 Jan 2020 Planned End Date changed from 1 Jan 2020 to 1 Jul 2021.
- 06 Jan 2020 Planned primary completion date changed from 1 Oct 2019 to 1 Apr 2021.
- 27 Nov 2018 Status changed from not yet recruiting to recruiting.